This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva should face trimmed US antitrust claims from Myan over Copaxone, special master recommends

( February 27, 2025, 23:31 GMT | Official Statement) -- MLex Summary: Teva Pharmaceuticals should be denied dismissal as to most allegations brought by Mylan in a US antitrust case over generic Copaxone, a special master recommended. Special Master Faith S. Hochberg said that Mylan has alleged a set of facts from which to plausibly infer that rebate agreements and switch agreements adversely affected competition, and the facts alleged are sufficient to survive the motions to dismiss. Hochberg did identify some allegations that are to be removed from Mylan’s Sherman Act count when it files its amended complaint. See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections